WuXi AppTec and WuXi Biologics are planning to sell some of their operations after the Chinese biotech companies were targeted by the U.S. on national security grounds, the Financial Times has reported. WuXi AppTec has put its cell and gene therapy manufacturing unit WuXi Advanced Therapies, which operates four laboratories and manufacturing facilities in Philadelphia, up for sale, the newspaper reported, citing people familiar with the matter. WuXi Biologics is working with advisers to test interest in some of its European production facilities, FT said.
Read the full article: China’s WuXi Explores Sale of Pharma Operations as US Restrictions Loom, FT Reports //
Source: https://www.reuters.com/markets/deals/chinas-wuxi-explores-sale-pharma-units-us-restrictions-loom-ft-reports-2024-10-03/